
Christine E Wright

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3994529/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cannabidiol selectively inhibits the contraction of rat small resistance arteries: Possible role for CGRP and voltage-gated calcium channels. European Journal of Pharmacology, 2021, 891, 173767.	1.7	4
2	Zinc drives vasorelaxation by acting in sensory nerves, endothelium and smooth muscle. Nature Communications, 2021, 12, 3296.	5.8	25
3	Pharmacological characterisation of the CB1 receptor antagonist activity of cannabidiol in the rat vas deferens bioassay. European Journal of Pharmacology, 2021, 909, 174433.	1.7	2
4	Role of Phospholipases A2 in Vascular Relaxation and Sympatholytic Effects of Five Australian Brown Snake, Pseudonaja spp., Venoms in Rat Isolated Tissues. Frontiers in Pharmacology, 2021, 12, 754304.	1.6	7
5	The β2-adrenoceptor agonist bronchodilators terbutaline and orciprenaline are also weak α1-adrenoceptor antagonists. European Journal of Pharmacology, 2020, 882, 173304.	1.7	3
6	Estimation of the vascular resistance amplifier in the renal vascular bed in conscious hypertensive rabbits: comparison with the total peripheral vasculature. Heliyon, 2020, 6, e03810.	1.4	0
7	Using high-resolution Twin-Ion Metabolite Extraction (HiTIME) mass spectrometry with stable isotope labelling to investigate the metabolism of valproic acid inÂvivo. International Journal of Mass Spectrometry, 2019, 444, 116187.	0.7	4
8	The effects of varying Mg2+ ion concentrations on contractions to the cotransmitters ATP and noradrenaline in the rat vas deferens. Autonomic Neuroscience: Basic and Clinical, 2019, 222, 102588.	1.4	2
9	Role of endothelin-1 clearance in the haemodynamic responses to endothelin-1 in the pulmonary and hindquarter vasculature of anaesthetised rats European Journal of Pharmacology, 2019, 855, 124-136.	1.7	0
10	Letter by Angus and Wright Regarding Article, "Pannexin-1 Channels as an Unexpected New Target of the Antihypertensive Drug Spironolactone― Circulation Research, 2018, 122, e86-e87.	2.0	0
11	Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau. Journal of Alzheimer's Disease, 2017, 56, 849-860.	1.2	23
12	Novel technique to determine the p K A of clonidine at prejunctional α 2 -adrenoceptors in cardiac and vascular sympathetic transmission. European Journal of Pharmacology, 2017, 800, 81-95.	1.7	0
13	Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro. European Journal of Pharmacology, 2017, 804, 111-116.	1.7	3
14	Distortion of K _B estimates of endothelinâ€1 ET _A and ET _B receptor antagonists in pulmonary arteries: Possible role of an endothelinâ€1 clearance mechanism. Pharmacology Research and Perspectives, 2017, 5, e00374.	1.1	7
15	Proteomics and antivenomics of Papuan black snake (Pseudechis papuanus) venom with analysis of its toxicological profile and the preclinical efficacy of Australian antivenoms. Journal of Proteomics, 2017, 150, 201-215.	1.2	22
16	Novel α1-adrenoceptor antagonism by the fluroquinolone antibiotic trovafloxacin. European Journal of Pharmacology, 2016, 791, 179-184.	1.7	16
17	Vascular reactivity of rabbit isolated renal and femoral resistance arteries in renal wrap hypertension. European Journal of Pharmacology, 2016, 773, 32-41.	1.7	4

Neutralization of the neuromuscular inhibition of venom and taipoxin from the taipan (Oxyuranus) Tj ETQq0 0 0 rg $_{0.4}^{BT}$ /Overlock 10 Tf 50 $_{0.4}^{CP}$

#	Article	IF	CITATIONS
19	ATP is not involved in α1-adrenoceptor-mediated vasoconstriction in resistance arteries. European Journal of Pharmacology, 2015, 769, 162-166.	1.7	11
20	Pannexin-1 channels do not regulate α1-adrenoceptor-mediated vasoconstriction in resistance arteries. European Journal of Pharmacology, 2015, 750, 43-51.	1.7	10
21	Contrasting cardiovascular properties of the µ-opioid agonists morphine and methadone in the rat. European Journal of Pharmacology, 2015, 762, 372-381.	1.7	9
22	High-Resolution Twin-Ion Metabolite Extraction (HiTIME) Mass Spectrometry: Nontargeted Detection of Unknown Drug Metabolites by Isotope Labeling, Liquid Chromatography Mass Spectrometry, and Automated High-Performance Computing. Analytical Chemistry, 2015, 87, 4104-4109.	3.2	23
23	Comparative study of the toxic effects of Chrysaora quinquecirrha (Cnidaria: Scyphozoa) and Chironex fleckeri (Cnidaria: Cubozoa) venoms using cell-based assays. Toxicon, 2015, 106, 57-67.	0.8	17
24	Synthesis of six mexiletine derivatives with isoindolines attached as potential antioxidants and their evaluation as cardioprotective agents. MedChemComm, 2015, 6, 634-639.	3.5	2
25	Combined venom gland cDNA sequencing and venomics of the New Guinea small-eyed snake, Micropechis ikaheka. Journal of Proteomics, 2014, 110, 209-229.	1.2	19
26	Membrane interactions and biological activity of antimicrobial peptides from Australian scorpion. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2140-2148.	1.4	28
27	Structure, Molecular Modeling, and Function of the Novel Potassium Channel Blocker Urotoxin Isolated from the Venom of the Australian Scorpion <i>Urodacus yaschenkoi</i> . Molecular Pharmacology, 2014, 86, 28-41.	1.0	21
28	The role of voltage-operated and non-voltage-operated calcium channels in endothelin-induced vasoconstriction of rat cerebral arteries. European Journal of Pharmacology, 2014, 742, 65-73.	1.7	9
29	Preclinical efficacy of Australian antivenoms against the venom of the small-eyed snake, Micropechis ikaheka, from Papua New Guinea: An antivenomics and neutralization study. Journal of Proteomics, 2014, 110, 198-208.	1.2	13
30	Efficacy of Australian red-back spider (Latrodectus hasselti) antivenom in the treatment of clinical envenomation by the cupboard spider Steatoda capensis (Theridiidae). Toxicon, 2014, 86, 68-78.	0.8	7
31	Vasoconstrictor Responses to Vasopressor Agents in Human Pulmonary and Radial Arteries. Anesthesiology, 2014, 121, 930-936.	1.3	98
32	Paul I Korner (1925–2012). Clinical and Experimental Pharmacology and Physiology, 2013, 40, 169-176.	0.9	0
33	A pharmacological investigation of the venom extract of the Australian box jellyfish, Chironex fleckeri, in cardiac and vascular tissues. Toxicology Letters, 2012, 209, 11-20.	0.4	27
34	Dual action molecules: Bioassays of combined novel antioxidants and angiotensin II receptor antagonists. European Journal of Pharmacology, 2012, 695, 96-103.	1.7	9
35	Exogenous glutathione is essential in the testing of antioxidant capacity using radical-induced haemolysis. Journal of Pharmacological and Toxicological Methods, 2012, 65, 142-146.	0.3	7
36	Novel paramagnetic AT1 receptor antagonists. Chemical Communications, 2011, 47, 12083.	2.2	11

#	Article	IF	CITATIONS
37	Analytical pharmacology and the elucidation of function. Trends in Pharmacological Sciences, 2011, 32, 235-241.	4.0	0
38	The pharmacology of Malo maxima jellyfish venom extract in isolated cardiovascular tissues: A probable cause of the Irukandji syndrome in Western Australia. Toxicology Letters, 2011, 201, 221-229.	0.4	14
39	Levosimendan preserves the contractile responsiveness of hypoxic human myocardium via mitochondrial KATP channel and potential pERK 1/2 activation. European Journal of Pharmacology, 2011, 655, 59-66.	1.7	22
40	A new approach to assessing the structural total peripheral resistance amplifier in renal (Page) hypertension in conscious rabbits. Journal of Hypertension, 2010, 28, 1862-1874.	0.3	8
41	A review of local anesthetic cardiotoxicity and treatment with lipid emulsion. Local and Regional Anesthesia, 2010, 3, 11.	2.8	44
42	Vascular Effects of FGF-2 and VEGF-B in Rabbits with Bilateral Hind Limb Ischemia. Journal of Vascular Research, 2009, 46, 45-54.	0.6	27
43	Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: Novel agonists for the CB1 receptor. European Journal of Medicinal Chemistry, 2008, 43, 513-539.	2.6	18
44	Advantages of a selective β-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. European Journal of Pharmacology, 2008, 587, 209-215.	1.7	44
45	Synthesis and Cannabinoid Activity of a Variety of 2,3-Substituted 1-Benzo[b]thiophen Derivatives and 2,3-Substituted Benzofuran: Novel Agonists for the CB1 Receptor. Australian Journal of Chemistry, 2008, 61, 484.	0.5	6
46	Adaptation of Hindquarter Vascular Reactivity to Femoral Artery Ligation and Hypercholesterolemia in the Rabbit. Journal of Vascular Research, 2008, 45, 279-294.	0.6	1
47	Persistent Depression of Contractility and Vasodilation with Propofol but Not with Sevoflurane or Desflurane in Rabbits. Anesthesiology, 2008, 108, 87-93.	1.3	51
48	Cardiac Tissue Engineering in an In Vivo Vascularized Chamber. Circulation, 2007, 115, 353-360.	1.6	216
49	Inoprotection: The Perioperative Role of Levosimendan. Anaesthesia and Intensive Care, 2007, 35, 845-862.	0.2	14
50	The Cardiovascular Effects of Adrenaline, Dobutamine and Milrinone in Rabbits Using Pressure-Volume Loops and Guinea Pig Isolated Atrial Tissue. Anaesthesia and Intensive Care, 2007, 35, 180-188.	0.2	13
51	The biology of vascular endothelial growth factor-B (VEGF-B). Pulmonary Pharmacology and Therapeutics, 2006, 19, 61-69.	1.1	79
52	Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. Thrombosis Research, 2006, 118, 755-762.	0.8	23
53	Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRÎ ³ deficiency. Blood, 2006, 107, 4346-4353.	0.6	134
54	Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals. Journal of Pharmacological and Toxicological Methods, 2006, 53, 20-29.	0.3	31

#	Article	IF	CITATIONS
55	CARDIOVASCULAR ACTIONS OF THE VENOM FROM THE IRUKANDJI (CARUKIA BARNESI) JELLYFISH: EFFECTS IN HUMAN, RAT AND GUINEA-PIG TISSUES IN VITRO AND IN PIGS IN VITRO. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 777-788.	0.9	60
56	Synergistic and additive interactions of the cannabinoid agonist CP55,940 with μ opioid receptor and α 2 -adrenoceptor agonists in acute pain models in mice. British Journal of Pharmacology, 2005, 144, 875-884.	2.7	84
57	Pl 3-kinase p110β: a new target for antithrombotic therapy. Nature Medicine, 2005, 11, 507-514.	15.2	555
58	Synergy between intrathecal ω-conotoxin CVID and dexmedetomidine to attenuate mechanical hypersensitivity in the rat. European Journal of Pharmacology, 2005, 506, 221-227.	1.7	10
59	Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain, 2004, 109, 124-131.	2.0	121
60	Cardiovascular reflex responses after intrathecal omega-conotoxins or dexmedetomidine in the rabbit. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 82-87.	0.9	2
61	Central endogenous histamine modulates sympathetic outflow through H3 receptors in the conscious rabbit. British Journal of Pharmacology, 2003, 139, 1023-1031.	2.7	6
62	Structural factors increase blood pressure through the interaction of resistance vessel geometry with neurohumoral and local factors: estimates in rabbits with renal cellophane-wrap hypertension with intact effectors and during neurohumoral blockade. Journal of Hypertension, 2002, 20, 471-483.	0.3	27
63	Actions of intrathecal ω-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. European Journal of Pharmacology, 2002, 451, 279-286.	1.7	158
64	Acute Effects Of L- And T-Type Calcium Channel Antagonists On Cardiovascular Reflexes In Conscious Rabbits. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 372-380.	0.9	4
65	Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 1035-1039.	0.9	18
66	The interactive vascular resistance amplifier and non-interactive reviewers. Journal of Hypertension, 2002, 20, 1023-1027.	0.3	7
67	Targeting voltage-gated Ca2+ channels. Lancet, The, 2001, 357, 1294.	6.3	1
68	Structure and the resistance amplifier in hypertension. Journal of Hypertension, 2000, 18, 235-239.	0.3	17
69	Postural hypotension following N-type Ca2+ channel blockade is amplified in experimental hypertension. Journal of Hypertension, 2000, 18, 65-73.	0.3	13
70	Cardiovascular and autonomic effects of ω-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. British Journal of Pharmacology, 2000, 131, 1325-1336.	2.7	51
71	Techniques to study the pharmacodynamics of isolated large and small blood vessels. Journal of Pharmacological and Toxicological Methods, 2000, 44, 395-407.	0.3	89
72	Techniques to measure pharmacodynamics in the intact vasculature. Journal of Pharmacological and Toxicological Methods, 2000, 44, 385-394.	0.3	9

#	Article	IF	CITATIONS
73	Pharmacological characterisation of cannabinoid CB1 receptors in the rat and mouse. European Journal of Pharmacology, 2000, 391, 151-161.	1.7	28
74	Targetting voltage-gated calcium channels in cardiovascular therapy. Lancet, The, 2000, 356, 1287-1289.	6.3	20
75	Role of NPY Y1 Receptors in Cardiovascular Control in the Conscious Rabbit. Journal of Cardiovascular Pharmacology, 2000, 35, 315-321.	0.8	4
76	Heterogeneity of prejunctional NPY receptor-mediated inhibition of cardiac neurotransmission. British Journal of Pharmacology, 1999, 127, 99-108.	2.7	5
77	Polypeptide ?-conotoxin GVIA as a basis for new analgesic and neuroprotective agents. Drug Development Research, 1999, 46, 206-218.	1.4	14
78	Enhanced total peripheral vascular responsiveness in hypertension accords with the amplifier hypothesis. Journal of Hypertension, 1999, 17, 1687-1696.	0.3	33
79	Exogenous NPY modulation of cardiac autonomic reflexes and its pressor effect in the conscious rabbit. British Journal of Pharmacology, 1998, 123, 1375-1384.	2.7	5
80	Endogenous Angiotensin II and Bradykinin Delay and Attenuate the Hypotension After N-Type Calcium Channel Blockade in Conscious Rabbits. Journal of Cardiovascular Pharmacology, 1998, 32, 951-961.	0.8	14
81	Structure-Function Relationships of ω-Conotoxin GVIA. Journal of Biological Chemistry, 1997, 272, 12014-12023.	1.6	95
82	Differential effects of ω-conotoxin GVIA on cholinergic and non-cholinergic secretomotor neurones in the guinea-pig small intestine. British Journal of Pharmacology, 1997, 121, 232-236.	2.7	5
83	Prolonged Cardiovascular Effects of the N-Type Ca2+ Channel Antagonist ω-Conotoxin GVIA in Conscious Rabbits. Journal of Cardiovascular Pharmacology, 1997, 30, 392-399.	0.8	14
84	Baroreflex resetting but no vascular tolerance in response to transdermal glyceryl trinitrate in conscious rabbits. British Journal of Pharmacology, 1996, 118, 93-104.	2.7	4
85	Effects of Nâ€, Pâ€-and Qâ€ŧype neuronal calcium channel antagonists on mammalian peripheral neurotransmission. British Journal of Pharmacology, 1996, 119, 49-56.	2.7	79
86	Distribution of N-type Ca2+ channel binding sites in rabbit brain following central administration of ω-conotoxin GVIA. European Journal of Pharmacology, 1996, 315, 11-18.	1.7	15
87	SELECTIVITY OF ω ONOTOXIN GVIA FOR Nâ€TYPE CALCIUM CHANNELS IN RAT ISOLATED SMALL MESENTER ARTERIES. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 16-21.	الر 0.9	21
88	Hemodynamic and Autonomic Reflex Effects of Chronic N-Type Ca2+ Channel Blockade with ω-Conotoxin GVIA in Conscious Normotensive and Hypertensive Rabbits. Journal of Cardiovascular Pharmacology, 1995, 25, 459-468.	0.8	21
89	-CONOTOXIN GVIA AND PRAZOSIN, BUT NOT FELODIPINE, CAUSE POSTURAL HYPOTENSION IN RABBITS. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 711-716.	0.9	16
90	THE EFFECTS OF CENTRAL ADMINISTRATION OF ?-CONOTOXIN GVIA ON CARDIOVASCULAR PARAMETERS AND AUTONOMIC REFLEXES IN CONSCIOUS RABBITS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 865-873.	0.9	10

#	Article	IF	CITATIONS
91	Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovascular Research, 1992, 26, 48-57.	1.8	565
92	Differences in regional vascular sensitivity to endothelinâ€1 between spontaneously hypertensive and normotensive Wistarâ€Kyoto rats. British Journal of Pharmacology, 1990, 100, 107-113.	2.7	41
93	Coronary circulation and 5-hydroxytryptamine. , 1990, , 365-378.		0
94	5-Carboxamidotryptamine Elicits 5-HT2 and 5-HT3 Receptor-Mediated Cardiovascular Responses in the Conscious Rabbit. Journal of Cardiovascular Pharmacology, 1989, 13, 557-564.	0.8	13
95	Regional vasodilation is a prominent feature of the haemodynamic response to endothelin in anaesthetized, spontaneously hypertensive rats. European Journal of Pharmacology, 1988, 155, 201-203.	1.7	194
96	Vascular amplifier properties in renovascular hypertension in conscious rabbits. Hindquarter responses to constrictor and dilator stimuli Hypertension, 1987, 9, 122-131.	1.3	88
97	Diverse Vascular Responses to Serotonin in the Conscious Rabbit. Journal of Cardiovascular Pharmacology, 1987, 10, 415-423.	0.8	18
98	ENDOTHELIUM-DEPENDENT RELAXATION IS UNALTERED BY HYPERTENSION, CHOLESTEROL OR INTIMAL THICKENING. Clinical and Experimental Pharmacology and Physiology, 1986, 13, 289-293.	0.9	7
99	HYPERTENSION ALTERS SLOPE AND RANGE BUT NOT SENSITIVITY TO VASOCONSTRICTOR AND VASODILATOR AGENTS IN THE RABBIT HINDQUARTER. Clinical and Experimental Pharmacology and Physiology, 1986, 13, 301-304.	0.9	1
100	Effects of hypertension and hypercholesterolemia on vasodilatation in the rabbit Hypertension, 1986, 8, 361-371.	1.3	43
101	Haemodynamic Response to Ketanserin in Rabbits with Page Hypertension: Comparison with Prazosin. Journal of Hypertension, 1983, 1, 183-190.	0.3	13